Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 1/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
| ▸ | EDNRA | P25101 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | CA12 | O43570 | 1/20 | 0.30 |
| ▸ | CA1 | P00915 | 1/20 | 0.30 |
| ▸ | CA2 | P00918 | 1/20 | 0.30 |
| ▸ | CA9 | Q16790 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL751 | 0.71 | PSIP1 (0.54) | HSD11B1TP53ALDH1A1CA12CA1 | |
| SCHEMBL12360342 | 0.71 | PTGDR2 (0.37) | HSD11B1EDNRAALDH1A1MAPT | |
| SCHEMBL3247012 | 0.69 | ALDH1A1 (0.50) | HSD11B1TP53ALDH1A1CA12CA1 | |
| Methane SCHEMBL8122177 | 0.69 | PSIP1 (0.52) | HSD11B1TP53ALDH1A1CA12CA1 | |
| SCHEMBL3272540 | 0.69 | HTR6 (0.39) | HSD11B1EDNRAALDH1A1 | |
| SCHEMBL10814408 | 0.69 | EDNRA (0.40) | EDNRA | |
| SCHEMBL4074745 | 0.68 | ENPP2 (0.45) | TP53 | |
| SCHEMBL2320786 | 0.68 | PSEN1 (0.46) | HSD11B1TP53ALDH1A1CA1CA2 | |
| SCHEMBL4079205 | 0.68 | F2 (0.41) | TP53CA12CA1CA2CA9 | |
| SCHEMBL1169954 | 0.68 | ALDH1A1 (0.55) | TP53ALDH1A1CA12CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6544981-B2 | Anticoagulants, cardiovascular disorders | BRISTOL-MYERS SQUIBB COMPANY | 2003-04-08 | — | — | US | disclosed |
| EP-1294716-A1 | LACTAM INHIBITORS OF FACTOR XA AND METHOD | Bristol-Myers Squibb Company (US) | 2003-03-26 | — | — | EP | disclosed |
| US-20020025957-A1 | Lactam inhibitors of factor Xa and method | BRISTOL-MYERS SQUIBB COMPANY | 2002-02-28 | — | — | US | disclosed |
| WO-2001096331-A1 | LACTAM INHIBITORS OF FACTOR XA AND METHOD | BRISTOL-MYERS SQUIBB COMPANY (US) | 2001-12-20 | — | — | WO | disclosed |
| US-5886195-A | REACTING AN APPROPRIATE CARBOXALDEHYDE WITH AN APPROPRIATE SULFONYLACETONITRILE | SUGEN, INC. (US) | 1999-03-23 | — | — | US | disclosed |
| US-5710173-A | ANTITUMOR AGENTS OR ANTICARCINOGENIC AGENTS | SUGEN, INC. (US) | 1998-01-20 | — | — | US | disclosed |
| WO-1996040675-A1 | THIENYL COMPOUNDS FOR INHIBITION OF CELL PROLIFERATIVE DISORDERS | SUGEN, INC. (US) | 1996-12-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020025957-A1 | Lactam inhibitors of factor Xa and method | F9, F7, F11 | HSD11B1 970/4885TP53 4848/4885EDNRA 2095/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.